Jenburkt Pharmaceuticals Ltd
JENBURPHJenburkt Pharmaceuticals Ltd
JENBURPHPrice Chart
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
18.26 | 3.82 | 1.22% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.35 | 6.54 | 0.51% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Jenburkt Pharmaceuticals Limited is engaged in the manufacture of pharmaceutical formulations. The Company offers prescription and over-the-counter drugs.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 96.32 | 106.27 | 118.06 | 126.05 | 123.11 | 113.60 | 128.93 | 141.87 | 146.64 | 154.05 | ||||||||||
Raw Materials | 28.89 | 32.51 | 30.51 | 38.75 | 33.55 | 26.91 | 33.72 | 31.67 | 30.80 | 110.50 | ||||||||||
Power & Fuel Cost | 0.57 | 0.53 | 0.61 | 0.59 | 0.59 | 0.50 | 0.61 | 0.76 | 0.75 | |||||||||||
Employee Cost | 21.49 | 25.21 | 27.69 | 31.20 | 36.51 | 32.38 | 36.49 | 38.81 | 42.49 | |||||||||||
Selling & Administrative Expenses | 26.11 | 26.61 | 27.30 | 28.10 | 25.46 | 23.03 | 24.32 | 29.03 | 31.04 | |||||||||||
Operating & Other expenses | 0.07 | -1.27 | 4.78 | -0.95 | 3.03 | 6.62 | 1.59 | 6.12 | 3.77 | |||||||||||
EBITDA | 19.19 | 22.68 | 27.17 | 28.36 | 23.97 | 24.16 | 32.20 | 35.48 | 37.79 | 43.55 | ||||||||||
Depreciation/Amortization | 1.99 | 1.79 | 1.50 | 1.35 | 2.30 | 2.04 | 1.90 | 2.26 | 2.34 | 2.41 | ||||||||||
PBIT | 17.20 | 20.89 | 25.67 | 27.01 | 21.67 | 22.12 | 30.30 | 33.22 | 35.45 | 41.14 | ||||||||||
Interest & Other Items | 0.38 | 0.41 | 0.41 | 0.39 | 0.53 | 0.47 | 0.43 | 0.37 | 0.27 | 0.36 | ||||||||||
PBT | 16.82 | 20.48 | 25.26 | 26.62 | 21.14 | 21.65 | 29.87 | 32.85 | 35.18 | 40.78 | ||||||||||
Taxes & Other Items | 6.05 | 6.97 | 8.05 | 6.83 | 6.27 | 5.14 | 7.58 | 8.25 | 9.20 | 10.49 | ||||||||||
Net Income | 10.77 | 13.51 | 17.21 | 19.79 | 14.87 | 16.51 | 22.29 | 24.60 | 25.98 | 30.29 | ||||||||||
EPS | 23.16 | 29.06 | 37.26 | 43.12 | 32.40 | 35.97 | 48.57 | 54.65 | 58.87 | 68.63 | ||||||||||
DPS | 7.20 | 8.10 | 9.00 | 10.20 | 8.10 | 10.20 | 12.00 | 14.40 | 15.30 | 15.30 | ||||||||||
Payout ratio | 0.31 | 0.28 | 0.24 | 0.24 | 0.25 | 0.28 | 0.25 | 0.26 | 0.26 | 0.22 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Jenburkt Pharmaceuticals Ltd | 21.28 | 3.82 | 1.22% |
Sun Pharmaceutical Industries Ltd | 45.34 | 6.47 | 0.75% |
Cipla Ltd | 31.21 | 4.80 | 0.82% |
Torrent Pharmaceuticals Ltd | 65.38 | 15.80 | 0.88% |
Price Comparison
Compare JENBURPH with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
Increasing Dividends
JENBURPH has increased dividends consistently over the last 5 years
Dividend Yield
Current dividend yield is 1.22%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹12.21 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 23, 2024
Dividend/Share
₹15.30
Ex DateEx Date
Jul 23, 2024
Cash Dividend
Ex DateEx DateJul 19, 2023
Dividend/Share
₹14.40
Ex DateEx Date
Jul 19, 2023
Cash Dividend
Ex DateEx DateJul 21, 2022
Dividend/Share
₹12.00
Ex DateEx Date
Jul 21, 2022
Cash Dividend
Ex DateEx DateAug 30, 2021
Dividend/Share
₹10.20
Ex DateEx Date
Aug 30, 2021
Cash Dividend
Ex DateEx DateMar 18, 2020
Dividend/Share
₹8.10
Ex DateEx Date
Mar 18, 2020
Net profit of Jenburkt Pharmaceuticals rose 31.15% to Rs 9.60 crore in the quarter ended September 2024 as against Rs 7.32 crore during the previous quarter ended September 2023. Sales rose 7.65% to Rs 41.22 crore in the quarter ended September 2024 as against Rs 38.29 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales41.2238.29 8 OPM %27.7323.77 - PBDT13.1610.13 30 PBT12.529.54 31 NP9.607.32 31 Powered by Capital Market - Live
Jenburkt Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 5 November 2024Powered by Capital Market - Live
Jenburkt Pharmaceuticals standalone net profit rises 38.18% in the June 2024 quarter
Net profit of Jenburkt Pharmaceuticals rose 38.18% to Rs 7.42 crore in the quarter ended June 2024 as against Rs 5.37 crore during the previous quarter ended June 2023. Sales rose 11.51% to Rs 32.54 crore in the quarter ended June 2024 as against Rs 29.18 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales32.5429.18 12 OPM %28.5523.85 - PBDT10.597.93 34 PBT10.077.43 36 NP7.425.37 38 Powered by Capital Market - Live
Jenburkt Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 26 July 2024.Powered by Capital Market - Live
Pharma stock declares ₹702 share buyback at a premium of 13%
Dividend paying pharma stock to consider share buyback
Jenburkt Pharmaceuticals standalone net profit rises 40.56% in the September 2021 quarter
Jenburkt Pharmaceuticals standalone net profit declines 16.02% in the March 2021 quarter
Stocks in news: ITC, Infosys, PVR, MTAR Tech, SBI, Panacea Biotec and Radico Khaitan
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 3.07%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.06% to 0.04%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 5.59%, vs industry avg of 15.28%